shutterstock_1234422481_edited.jpg
 

R&D Pipeline Overview

AmMax has established a robust pipeline targeting CSF1R. In addition to tenosynovial giant cell tumor wherein an

overexpression of CSF1 drives the pathogenesis, AmMax’s pipeline addresses a number of other diseases with critical unmet medical needs, such as idiopathic pulmonary fibrosis and polycystic kidney diseases, by leveraging the dual action of AMB-05X on inflammation and fibrosis.

The technology basis for AmMax’s platform stems from the critical yet diverse roles played by the CSF1/CSF1R pathway. Via research collaboration with academic institutions, we continue to expand our pipeline to unlock the full potential of the CSF1R platform.

Animal POC

Preclinical

Phase 1

Phase 2

Phase 3

Animal POC

Exploratory

Preclinical

Phase I

Phase II

Phase III

Exploratory

Animal POC

Preclinical

Phase I

Phase II

Phase III

Exploratory

Animal POC

Phase I

Preclinical

Phase II

Phase III

Peptide

Exploratory

Animal POC

IND Enabling

Phase I

Phase II

Phase III

Undisclosed

AMB-057

Exploratory

Animal POC

Phase I

Preclinical

Phase II

Phase III

AMB-057

Pharmaceutical

©2021 BY AMMAX BIO INC